ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Multimodal PET-MR segmentation for glioblastoma: complementarity for treatment planning and recurrence definition.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundIn patients with Glioblastoma (GBM), Magnetic Resonance (MR) is used for tumour diagnosis and treatment planning. Positron Emission Tomography (PET) with O-(2)-18 F-Fluoroethyl-L-Tyrosine (FET) has been recommended to distinguish local recurrence from radiogenic alterations. However, clinical practice remains hindered by the time and expertise required for tumour and organs-at-risk (OARs) segmentation and the limited evidence of the added value of PET and its restricted availability across clinical centres. This study presents automatic segmentation models and a comprehensive evaluation of PET/MR complementary biological information for recurrent disease definition.
methodsThe nnU-Net was employed for segmentation using manually defined contours on 1,610 patients from 33 institutions. Model performance was evaluated by Dice-Sørensen-Coefficient (DSC). PET/MR recurrence complementarity was evaluated in 185 patients by Wilcoxon-Signed-Rank test (WSRT), DSC and radiomic features (RF). In RF analysis, MR-Enhancing subregions were classified as MR∩PET or MR-Only, based on overlap with PET. For MR-RF showing significant MR∩PET/MR-Only differences (WSRT), discrimination was further assessed by classifying RF for 3 × 3 × 3-voxel subregions within MR-Enhancing in two volumes (greater/less than the RF cohort median) and evaluating Positive-Predictive-Value and Sensitivity with MR∩PET/MR-Only.
resultsModels' performance in the test set resulted in DSC(MR-Enhancing) = 0.76 ± 0.24, DSC(MR-Edema) = 0.69 ± 0.23, DSC(PET-Uptake) = 0.71 ± 0.20, DSC(Planning-Target-Volume) = 0.93 ± 0.05, DSC(OARs) = 0.70 ± 0.13. Manual MR and FET-PET based GBM recurrence delineations differed significantly in size (p = 0.0497) and location (DSC = 0.45 ± 0.20). From the 37 MR-RF showing significant differences between MR∩PET and MR-Only (p < 0.05), none of the MR-Enhancing based RF-maps allowed spatial identification of PET findings (positive-predictive-value and sensitivity < 0.6).
conclusionsThe resulted segmentation models could facilitate PET/MR integration in GBM treatment. PET/MR comparison supports the complementarity of FET-PET.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.